Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group
-
- Trudy D. Buitenkamp
- Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital, Rotterdam, The Netherlands;
-
- Shai Izraeli
- Department of Paediatric Haemato-Oncology, Edmond and Lily Safra Children’s Hospital, Sheba Medical Centre, Tel-Hashomer, Ramat Gan, and Tel Aviv University Medical School, Tel Aviv, Israel;
-
- Martin Zimmermann
- Statistical Office of Berlin-Frankfurt-Münster Study Group, Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany;
-
- Erik Forestier
- Department of Medical Biosciences, University of Umeå, Umeå, Sweden;
-
- Nyla A. Heerema
- Department of Pathology, The Ohio State University, Columbus, OH;
-
- Marry M. van den Heuvel-Eibrink
- Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital, Rotterdam, The Netherlands;
-
- Rob Pieters
- Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital, Rotterdam, The Netherlands;
-
- Carin M. Korbijn
- Dutch Childhood Oncology Group, The Hague, The Netherlands;
-
- Lewis B. Silverman
- Dana-Farber Cancer Institute, Boston, MA;
-
- Kjeld Schmiegelow
- Pediatric and Adolescent Medicine, the Juliane Marie Centre, the University Hospital Rigshospitalet, Copenhagen, Denmark;
-
- Der-Cheng Liang
- Pediatric Hematology-Oncology Division, Mackay Memorial Hospital, Taipei, Taiwan;
-
- Keizo Horibe
- Clinical Research Center, National Hospital Organization, Nagoya Medical Center, Nagoya, Aichi, Japan;
-
- Maurizio Arico
- Department Pediatric Hematology Oncology, Azienda Ospedaliero-Universitaria Meyer Children Hospital, Florence, Italy;
-
- Andrea Biondi
- Departement of Pediatrics, Univerty of Milano-Bicocca, Ospedale S. Gerardo, Monza, Italy;
-
- Giuseppe Basso
- Pediatric Hemato-Oncology, Department of Pediatrics “Salus Pueri,” University of Padua, Padova, Italy;
-
- Karin R. Rabin
- Division of Pediatric Hematology/Oncology, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX;
-
- Martin Schrappe
- Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany;
-
- Gunnar Cario
- Department of Pediatrics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany;
-
- Georg Mann
- Children's Cancer Research Institute, St. Anna Children’s Hospital, University Medical School Vienna, Vienna, Austria;
-
- Maria Morak
- Children's Cancer Research Institute, St. Anna Children’s Hospital, University Medical School Vienna, Vienna, Austria;
-
- Renate Panzer-Grümayer
- Children's Cancer Research Institute, St. Anna Children’s Hospital, University Medical School Vienna, Vienna, Austria;
-
- Veerle Mondelaers
- Department of Pediatric Hemato-Oncology, Ghent University Hospital, Belgium;
-
- Tim Lammens
- Department of Pediatric Hemato-Oncology, Ghent University Hospital, Belgium;
-
- Hélène Cavé
- Assistance Publique, Hôpitaux de Paris, Hôpital Robert Debré, Département de Génétique Université Paris-Denis Diderot, Paris, France;
-
- Batia Stark
- Center of Pediatric Hematology/Oncology, Schneider Children's Medical Center of Israel, Petah Tiqwa, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
-
- Ithamar Ganmore
- Department of Paediatric Haemato-Oncology, Edmond and Lily Safra Children’s Hospital, Sheba Medical Centre, Tel-Hashomer, Ramat Gan, and Tel Aviv University Medical School, Tel Aviv, Israel;
-
- Anthony V. Moorman
- Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle-upon-Tyne, United Kingdom;
-
- Ajay Vora
- Department of Haematology, Sheffield Children’s Hospital, Sheffield, United Kingdom;
-
- Stephen P. Hunger
- Department of Pediatrics, University of Colorado School of Medicine and Children’s Hospital, Aurora, CO;
-
- Ching-Hon Pui
- Department of Oncology and
-
- Charles G. Mullighan
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN;
-
- Atsushi Manabe
- Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan;
-
- Gabriele Escherich
- Clinic of Pediatric Hematology and Oncology, University Medical Center Hamburg–Eppendorf, Hamburg, Germany;
-
- Jerzy R. Kowalczyk
- Department of Children’s Hematology and Oncology, Medical University, Lublin, Poland; and
-
- James A. Whitlock
- Division of Haematology/Oncology, the Hospital for Sick Children, University of Toronto, Toronto, Canada
-
- C. Michel Zwaan
- Pediatric Oncology/Hematology, Erasmus MC–Sophia Children’s Hospital, Rotterdam, The Netherlands;
抄録
<jats:title>Key Points</jats:title> <jats:p>Although the risk of ALL relapse is significantly higher in children with DS, good-prognosis subgroups have been identified. Patients with DS-ALL have higher treatment-related mortality throughout the treatment period independent of the therapeutic regimen.</jats:p>
収録刊行物
-
- Blood
-
Blood 123 (1), 70-77, 2014-01-02
American Society of Hematology